The development of a potent new passive immunotherapeutic for the treatment and prevention of bacterial sepsis and septic shock. Bacterial sepsis and septic shock is a leading cause of death in hospital intensive care units and represents a significant public health burden. By developing a new passive immunotherapeutic regimen to treat and prevent bacterial sepsis and septic shock, the project aims to reverse the significant mortality and morbidity associated with this condition.